View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, Oct. 25 (HealthDay News) -- Vizamyl (flutemetamol F 18 injection) has been approved by the U.S. Food and Drug Administration for use with positron emission tomography (PET) imaging of the brain to screen adults for signs of Alzheimer's disease and other forms of dementia.
Vizamyl, combined with a PET scan, can help doctors detect beta amyloid protein, the FDA said Friday in a news release.
Vizamyl, the second diagnostic drug approved for this purpose, was evaluated in clinical studies of 761 people. The injected drug is not meant to predict whether a person will go on to develop Alzheimer's or other types of dementia, or to evaluate how people may respond to dementia therapies, the FDA warned.
Potential side effects of the drug include allergic-like reaction, becoming flushed, headache, a rise in blood pressure, nausea, and dizziness, the agency said.
Vizamyl is produced for GE Healthcare by Medi-Physics Inc., based in Arlington Heights, Ill.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top